1. Home
  2. JFU vs GRML Comparison

JFU vs GRML Comparison

Compare JFU & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 9F Inc.

JFU

9F Inc.

HOLD

Current Price

$2.63

Market Cap

30.6M

Sector

Finance

ML Signal

HOLD

Logo Greenland Mines Ltd. Common Stock

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.18

Market Cap

34.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
JFU
GRML
Founded
2006
N/A
Country
China
United States
Employees
N/A
5
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
30.6M
34.9M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
JFU
GRML
Price
$2.63
$0.18
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.5K
7.3M
Earning Date
12-09-2022
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.53
$0.16
52 Week High
$9.48
$0.55

Technical Indicators

Market Signals
Indicator
JFU
GRML
Relative Strength Index (RSI) 50.98 42.26
Support Level N/A $0.16
Resistance Level $2.88 $0.30
Average True Range (ATR) 0.13 0.03
MACD 0.04 0.00
Stochastic Oscillator 60.00 15.20

Price Performance

Historical Comparison
JFU
GRML

About JFU 9F Inc.

9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: